🔸 OTC Markets: $LMMY | Exousia Bio is the leader in exosome-based biotechnology, based on proprietary manufacturing, research, and clinical technology.
Blown away by the @ExousiaBio $LMMY $MAJI Projenicyte JV presentation #REMIJPM How can u not be excited about this potential #GBM treatment going through the regulatory process. Pay attention to the beginning. Replay it a couple of times. Let it sink in. Let’s get some engagement. #JPM2026 #biotechshowcase #Glioblastoma
Exousia Pro - $MAJI - unveils the full spectrum power of Maxasome™! This isn't just a supplement—it's cellular armor delivered by 100% Pure Exosomal Technology. Maxasome™, derived from Yellow Oyster Mushrooms, provides a potent, natural blend of Ergothioneine (EGT), Beta-glucans, and Vitamin D2. The sublingual (under the tongue) dropper ensures rapid delivery directly to your mitochondria and cell nucleus, providing unmatched protection for Longevity and Cognitive Vitality. Help Maximize your healthspan!
$LMMY completes acquisition of cancer therapy innovator Exousia AI and secures Orphan Drug Designation for its Glioblastoma therapy. Major preclinical wins and exclusive exosome tech set the stage for rapid growth. Read the PR: https://t.co/a0lcJksoBE
Welcome Shareholders to the Official “X” Account for Exousia Bio Inc. ( $LMMY ) - In just a few days, we will begin to release our first major update, formally kicking off what we believe will be a transformative and thrilling journey for the company.